RxDoctor Payments DataLook up a doctor →

Georgios Kotzias, DPM

Podiatrist · Paramus, NJNPI 1376942664

Payments from drug & device makers

$18,857in general payments, 2019–2025

Across 431 payments — averaging $43.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$5K
  • Smith+Nephew$3K
  • Seapearl East, Inc$2K
  • Kerecis Limited$1K
  • Zimmer Biomet$1K
  • Treace Medical Concepts, Inc.$1K
  • plus $5K from 41 others

What the payments were for

  • Travel & lodging$2,92015%
  • Food & beverage$13,87774%
  • Education$2,06011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,857 in reported general payments places this provider in the 95th percentile of 382 podiatrist providers in New Jersey.

See all podiatrist providers in New Jersey

Medicare billing

Part B allowed, 2024
$404,688
Medicare patients
846
Services billed
4,547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.71$30,116
RegranexBecaplermin11$22,795
Ammonium Lactate166$3,521
Diclofenac Sodium30$1,881
Mupirocin129$1,173
Ciclopirox13$578
Clindamycin Hcl24$275
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip14$223
ErythromycinErythromycin Base In Ethanol12$219
Methylprednisolone21$181
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav21$159
Ibuprofen12$97
Meloxicam12$21

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl, Regranex$2,714$52,91182 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 382 podiatrist providers in New Jersey.

Other podiatrist in Paramus

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →